Skip to main content
Fig. 2 | Journal of Experimental & Clinical Cancer Research

Fig. 2

From: The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer

Fig. 2

CUDC-907 results in dose-dependent downregulation of MYC paralogs and DDR pathway genes. a Western blot analysis of the basal expression of MYC paralogs in a panel of SCLC cell lines. b, c Western blot analysis of MYC paralogs in cells with amplification of MYC paralogs (b) and DDR pathway genes (c) in a panel of SCLC cell lines after treated with increased concentrations of CUDC-907 for 24 h

Back to article page